Multiple Myeloma Excellence Forum

Multiple Myeloma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Conference Coverage

Exploring Promising Novel Advances in the Multiple Myeloma Treatment Landscape

04/05/2024

Featuring Joshua Richter, MD

Joshua Richter, MD, discusses promising novel advances in the multiple myeloma treatment landscape, including the use of T-cell redirection therapy and possible treatment approvals to come.

Joshua Richter, MD, discusses...

04/05/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Should MRD-Based Decision-Making be Utilized in Multiple Myeloma Treatment Strategies?

04/05/2024

Featuring Joshua Richter, MD

At the 2024 Great Debates & Updates in Hematologic Malignancies, Joshua Richter, MD, explores the role of minimal residual disease in multiple myeloma treatment strategies, addressing whether it should be used to make clinical decisions for...

At the 2024 Great Debates &...

04/05/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Optimal Use of Bispecific Antibodies for Multiple Myeloma Treatment

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, University of California – San Francisco, San Francisco, California, discusses the role of bispecific antibodies in the treatment of patients with multiple...

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Evaluating the Potential Value of MRD as a Predictive Variable for Multiple Myeloma

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

Role of CD38 Monoclonal Antibodies and Bispecific Antibodies in Treating Multiple Myeloma

02/23/2024

Featuring Ajai Chari, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.

At the Lymphoma, Leukemia &...

02/23/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

02/13/2024

Featuring Suzanne Lentszch, MD, PhD

Featuring Suzanne Lentszch, MD, PhD ...

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.

At the 2023 Lymphoma, Leukemia &...

02/13/2024

Lymphoma, Leukemia & Myeloma Network

Conference Coverage

CAR-T Cell Therapy vs Stem Cell Transplant for the Treatment of Patients With Multiple Myeloma

01/24/2024

Featuring Adriana Rossi, MD

During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.

During a debate at the 2023...

01/24/2024

Lymphoma, Leukemia & Myeloma Network

Dan Vogl, MD, University of Pennsylvania

Conference Coverage

Evaluating Bispecific T-Cell Engagers for the Treatment of Patients With Multiple Myeloma

01/23/2024

Featuring Dan Vogl, MD

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.

During the 2023 Lymphoma,...

01/23/2024

Lymphoma, Leukemia & Myeloma Network

Faith E. Davies, MD, Perlmutter Cancer Center

Conference Coverage

Choosing a Treatment Strategy for Patients With Early Relapsed Multiple Myeloma

01/22/2024

Featuring Faith E. Davies, MD

During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.

During the 2023 Lymphoma,...

01/22/2024

Lymphoma, Leukemia & Myeloma Network

Carlyn Rose Tan, MD, Memorial Sloan Kettering Cancer Center

Conference Coverage

Prior Exposure to TCRT Associated With Lower CRS Incidence During Teclistamab Step-Up Dosing Phase Among Patients With R/R MM

01/22/2024

Featuring Carlyn Rose Tan, MD

At the 65th ASH Annual Meeting, Carlyn Rose Tan, MD, presented data that for patients with R/R multiple myeloma, exposure to a T-cell redirection therapy correlated with a lower incidence of cytokine release syndrome during the teclistamab...

At the 65th ASH Annual Meeting,...

01/22/2024

Oncology

Section Editor

Shaji Kumar, MD

Mayo Clinic, Rochester, Minnesota

Multiple Myeloma Excellence Forum

Section Editor

Specialties

Events

Year Round Education

HMP Global Products